NCT06298266View on ClinicalTrials.gov

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
BIOLOGICAL

infusion of GPRC5D-CD19 CAR T injection

Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

510317

Guangdong Second Provincial General Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Second Provincial General Hospital

OTHER

NCT06298266 - To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter